Your session is about to expire
← Back to Search
Other
A Study to Compare Zavegepant Concentration Using Samples Collected From the Vein Versus Patient-Centric Microsampling
Phase 1
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up screening to follow-up (day 30 to 37)
Awards & highlights
No Placebo-Only Group
Summary
This trial will study the effects of a drug called zavegepant using two different patient-centric devices for collecting liquid and dried blood samples. Taste assessments will also be done before and after administration. 14 people will participate for 9 weeks.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ screening to follow-up (day 30 to 37)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~screening to follow-up (day 30 to 37)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Number of Participants With Clinical Laboratory Abnormalities
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Zavegepant 10 mg Intranasal (IN)Experimental Treatment1 Intervention
All participants will receive zavegepant 10 mg IN spray in period 1 and a butterscotch candy + zavegepant 10 mg IN spray in period 2
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Zavegepant 10 mg IN
2023
Completed Phase 1
~20
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
PfizerLead Sponsor
4,670 Previous Clinical Trials
17,826,917 Total Patients Enrolled
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,553 Previous Clinical Trials
14,867,816 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a history of important health problems affecting your blood, kidneys, hormones, lungs, digestive system, heart, liver, brain, or mental health. This includes allergies to medications, but not mild seasonal allergies that are not causing any symptoms when the study drug is given.You have a history of frequent seizures or epilepsy, or have had your gallbladder removed due to gallstones.You have any other medical or mental health condition, including recent thoughts of self-harm or abnormal lab results, or any condition related to the COVID-19 pandemic that may make it unsafe for you to participate in the study.You have signs of organ problems or significant physical abnormalities that are not typical for the group of people being studied.
Research Study Groups:
This trial has the following groups:- Group 1: Zavegepant 10 mg Intranasal (IN)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.